Investing in GSK
GSK is a UK-based global healthcare company. We have a significant global commercial presence in more than 150 markets, a network of 86 manufacturing sites in 36 countries and large R&D centres in the UK, USA, Spain, Belgium and China. In recent years, GSK has focused its business around three strategic priorities which aim to increase growth, reduce risk and improve long-term financial performance.
As a global healthcare company, our commercial success depends on creating innovative new medicines, vaccines and healthcare products and making these accessible to as many people who need them as possible. Our performance in 2013 represented further strong delivery for the Group. We met our guidance with core EPS growth of 4% and sales growth of 1% (+3% ex-divestments) and returned £5.2 billion to shareholders via further growth in the dividend and our continuing share buy-back programme.
We also delivered the most productive period of R&D output in the company’s history and led the sector for new medicine approvals.
We are committed to using free cash flow to support increasing dividends, share repurchases or, where returns are more attractive, bolt-on acquisitions.